What is LMNL's Intrinsic value?

Liminal BioSciences Inc (LMNL) Intrinsic Value Analysis

Executive Summary

As of June 19, 2025, Liminal BioSciences Inc's estimated intrinsic value ranges from $2.92 to $2.92 per share, depending on the valuation methodology applied.

Valuation Method Fair Value (USD) Implied Upside/Downside
Dividend Discount Model (Stable) $2.92 -65.6%

Is Liminal BioSciences Inc (LMNL) undervalued or overvalued?

With the current market price at $8.50, the stock appears to be significantly overvalued.

Understanding Intrinsic Value

Intrinsic value represents the "true" worth of a company based on its fundamentals rather than market sentiment. We've employed multiple methodologies to triangulate Liminal BioSciences Inc's intrinsic value, including:

  1. Dividend Discount Model (DDM): Values the company based on expected future dividend payments

Weighted Average Cost of Capital (WACC)

The cost of capital is a critical factor in valuation models, representing the required return for investors.

WACC Component Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 0.69 0.77
Cost of equity 7.0% 9.2%
Cost of debt 5.5% 7.0%
Tax rate 0.2% 0.9%
Debt/Equity ratio 0.04 0.04
After-tax WACC 7.0% 9.1%

Valuation Methods

2. Dividend Discount Model (DDM)

The DDM values a company based on its expected future dividend payments. We used two approaches:

Multi-Stage DDM:

  • Current payout ratio: 0.0%
  • Stable payout ratio: 90.0%
  • Growth transition: 5 years
  • Cost of equity: 8.1%
  • Long-term growth rate: 4.0%
  • Fair value: $-130.41 (-1634.2% from current price)

Stable DDM:

  • Stable payout ratio: 70% (Low) to 90% (High)
  • Cost of equity: 9.2% (Low) to 7.0% (High)
  • Long-term growth rate: 3.0% (Low) to 5.0% (High)
  • Fair value range: $2 to $6
  • Selected fair value: $2.92 (-65.6% from current price)

Key Financial Metrics

Metric Value
Market Capitalization $28M
Enterprise Value $14M
Trailing P/E 81.04
Forward P/E 81.04
Trailing EV/EBITDA 9.70
Current Dividend Yield 0.00%
Dividend Growth Rate (5Y) 0.00%
Debt-to-Equity Ratio 0.04

Investment Decision Framework

To determine the most reliable intrinsic value estimate, we weigh each valuation method based on:

  1. Forecast Certainty: DCF methods rely on long-term projections, while earnings power value focuses on current normalized earnings
  2. Business Model Alignment: Dividend models are more appropriate for mature companies with established dividend policies
  3. Historical Accuracy: How well each method has predicted fair value historically

Valuation Weight Matrix

Valuation Method Weight Weighted Value
Dividend Discount Model (Stable) 100% $0.44
Weighted Average 100% $2.92

Investment Conclusion

Based on our comprehensive valuation analysis, Liminal BioSciences Inc's weighted average intrinsic value is $2.92, which is approximately 65.6% below the current market price of $8.50.

Key investment considerations:

  • Strong projected earnings growth (-7211% to -4092% margin)
  • Consistent cash flow generation
  • Conservative capital structure (Debt/Equity of 0.04)

Given these factors, we believe Liminal BioSciences Inc is currently significantly overvalued with the potential for long-term appreciation based on the company's growth trajectory and financial strength.